Disease · MONDO_0006572
Comparisons in its trials13
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 13 of 13
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Ruxolitinib Cream 1.5% BID vs Vehicle Cream BID: deaths from any cause | 0 of 60 | 0 of 32 | 92 | NCT05593432 | Trial comparisons |
| Ruxolitinib Cream 1.5% BID vs Vehicle Cream BID: serious adverse events | 0 of 60 | 0 of 32 | 92 | NCT05593432 | Trial comparisons |
Double-Blind, Vehicle-Controlled Period: Ruxolitinib Cream 1.5% BID vs Double-Blind, Vehicle-Controlled Period: Vehicle Cream BID: Number of Participants With Any Treatment-emergent Adverse Event (TEAE) During the Double-blind, Vehicle-controlled Period | 15 of 31 | 9 of 32 | 63 | NCT05593432 | Trial comparisons |
Double-Blind, Vehicle-Controlled Period: Ruxolitinib Cream 1.5% BID vs Double-Blind, Vehicle-Controlled Period: Vehicle Cream BID: Number of Participants With Any ≥Grade 3 TEAE During the Double-blind, Vehicle-controlled Period | 0 of 31 | 0 of 32 | 63 | NCT05593432 | Trial comparisons |
Open-Label Extension Period: Ruxolitinib Cream 1.5% BID vs Open-Label Extension Period: Vehicle Cream to Ruxolitinib Cream 1.5% BID: Number of Participants With Any ≥Grade 3 TEAE During the Open-label Extension Period | 0 of 30 | 1 of 29 | 59 | NCT05593432 | Trial comparisons |
Open-Label Extension Period: Ruxolitinib Cream 1.5% BID vs Open-Label Extension Period: Vehicle Cream to Ruxolitinib Cream 1.5% BID: Number of Participants With Any TEAE During the Open-label Extension Period | 8 of 30 | 11 of 29 | 59 | NCT05593432 | Trial comparisons |
| KPL-716 vs Placebo: deaths from any cause | 0 of 39 | 0 of 19 | 58 | NCT03858634 | Trial comparisons |
| KPL-716 vs Placebo: serious adverse events | 1 of 39 | 0 of 19 | 58 | NCT03858634 | Trial comparisons |
| Etanercept vs Placebo Injection: serious adverse events | 1 of 24 | 0 of 14 | 38 | NCT00285779 | Trial comparisons |
| Etanercept vs Placebo Injection: Count of Patients Achieving a Response in Cutaneous or Mucosal Disease at 24 Weeks | 4 of 13 | 5 of 14 | 27 | NCT00285779 | Trial comparisons |
| Pimecrolimus 1% Cream vs Vehicle Cream: serious adverse events | 0 of 10 | 0 of 11 | 21 | NCT00297037 | Trial comparisons |
| Cutaneous LP vs Dose Escalation Extension Group: deaths from any cause | 0 of 12 | 0 of 5 | 17 | NCT05188521 | Trial comparisons |
| Cutaneous LP vs Dose Escalation Extension Group: serious adverse events | 1 of 12 | 0 of 5 | 17 | NCT05188521 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0006572/comparisons